NEREUS™ (tradipitant)
Atopic Dermatitis
Key Facts
About Vanda Pharmaceuticals
Founded in 2003 and publicly traded on NASDAQ (VNDA), Vanda Pharmaceuticals leverages genetics and genomics to inform drug discovery and development. The company has achieved significant milestones with FDA approvals for Fanapt® (2009) and HETLIOZ® (2014), and continues to expand its pipeline with late-stage candidates like tradipitant and imsidolimab. Vanda's strategic focus combines commercial execution with a science-driven approach to address complex disorders in circadian rhythms, psychiatry, and inflammation.
View full company profileAbout Vanda Pharmaceuticals
Founded in 2003 and publicly traded on NASDAQ (VNDA), Vanda Pharmaceuticals leverages genetics and genomics to inform drug discovery and development. The company has achieved significant milestones with FDA approvals for Fanapt® (2009) and HETLIOZ® (2014), and continues to expand its pipeline with late-stage candidates like tradipitant and imsidolimab. Vanda's strategic focus combines commercial execution with a science-driven approach to address complex disorders in circadian rhythms, psychiatry, and inflammation.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Lebrikizumab | Eli Lilly | Phase 3 |
| Dupixent | Sanofi | Commercial |
| ASP2408 | Astellas Pharma | Phase 2 |
| KW-6356 | Kyowa Kirin | Phase 2 |
| KHK4083 | Kyowa Kirin | Phase 2 |
| Opzelura (ruxolitinib cream) | Ono Pharmaceutical | Approved |
| ONO-7913 | Ono Pharmaceutical | Phase 2 |
| KT-474 | Kymera Therapeutics | Phase 2 |
| GRC 27864 | Glenmark Pharmaceuticals | Phase 2 |
| ARQ-234 | Arcutis Biotherapeutics | Preclinical/Phase 1 |
| STAR-0310 | BioCryst Pharmaceuticals | Phase 1 |
| Rezpegaldesleukin | Nektar Therapeutics | Phase 2b |